Clinical trial · Observational
European CML Blast Crisis Register
NCT03869502CI-TRIAL-00066317BlastCrisisunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Multicentric prospective and retrospective register collecting patient with CML blast crisis diagnosed in Germany and Europe
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia in Myeloid Blast Crisis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- through study completion in 2024
- description
- how many patients survive after a blast crisis event
Secondary outcomes (3)
- measure
- Rate of hematologic response to treatment
- timeFrame
- through study completion in 2024
- description
- how many patients have a hematologic response to the local standard Treatment after a blast crisis event
- measure
- Rate of molecular response to treatment
- timeFrame
- through study completion in 2024
- description
- how many patients have a molecular response to the local standard Treatment after a blast crisis event
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>18 years * Diagnosis of BCR-ABL positive CML blast crisis according to the WHO criteria: * Blasts 20% or more of peripheral blood white cells or bone marrow cells or * Extramedullary blast proliferation or * Large foci or clusters of blasts in bone marrow biopsy Exclusion Criteria: * Lack of informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.